Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Nigel James Blumire

Doris Riether

Monika Ermann

Renee M Zindell

Angela Kay Berry

Innocent Mushi

Eugene R Hickey

David S Thomson

Alessandra Bartolozzi

Pier Francesco Cirillo

Lifen Wu

Christopher Francis Palmer

Patricia Amouzegh

Someina Khor

James Edward Jenkins

Achim Sauer

Stephen East

Malcolm Taylor

Markus Ostermeier

Robert John Scott

Eugene Richard Hickey

Stephen Peter East

Chandana Parke

Edward Thomas Glenn

Przemyslaw Zawadzki

Chandana Chowdhury

David Smith Thomson

Nigel Ermann

Edward Glenn

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Compounds which modulate the CB2 receptor

Compounds which selectively modulate the CB2 receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. 

Therapeutic uses of compounds which selectively modulate the CB2 receptor

are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Compound of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Growing community of inventors

Abingdon, United Kingdom

Nigel James Blumire